CVAC
CureVac N.V.

6,470
Mkt Cap
$1.19B
Volume
377,086.00
52W High
$5.72
52W Low
$2.37
PE Ratio
5.84
CVAC Fundamentals
Price
$5.30
Prev Close
$5.30
Open
$5.30
50D MA
$5.36
Beta
0.99
Avg. Volume
452,302.70
EPS (Annual)
$0.7819
P/B
1.71
Rev/Employee
$588,910.74
Loading...
Loading...
News
all
press releases
Twist Bioscience (TWST) Reports Q4 Loss, Tops Revenue Estimates
Twist Bioscience (TWST) delivered earnings and revenue surprises of -12.50% and +1.69%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5h ago
News Placeholder
More News
News Placeholder
Quinn Opportunity Partners LLC Acquires 204,073 Shares of CureVac N.V. $CVAC
Quinn Opportunity Partners LLC grew its stake in CureVac N.V. (NASDAQ:CVAC - Free Report) by 305.3% during the second quarter, according to the company in its most recent filing with the Securities...
MarketBeat·5h ago
News Placeholder
Amphastar Pharmaceuticals (AMPH) Q3 Earnings and Revenues Top Estimates
Amphastar (AMPH) delivered earnings and revenue surprises of +20.78% and +3.96%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·8d ago
News Placeholder
Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Beats Revenue Estimates
Foghorn Therapeutics (FHTX) delivered earnings and revenue surprises of +19.35% and +1.12%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·9d ago
News Placeholder
Oncobiologics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates
Oncobiologics (OTLK) delivered earnings and revenue surprises of -4.76% and -40.98%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Kamada (KMDA) Q2 Earnings Top Estimates
Kamada (KMDA) delivered earnings and revenue surprises of +44.44% and -0.67%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Coya Therapeutics, Inc. (COYA) Reports Q2 Loss, Lags Revenue Estimates
Coya Therapeutics, Inc. (COYA) delivered earnings and revenue surprises of -63.64% and -96.10%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Lags Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of -2.33% and -84.39%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates
Beam Therapeutics (BEAM) delivered earnings and revenue surprises of +3.85% and -38.59%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Deutsche Bank bearish on European pharma stocks into Q2 amid political headwinds
Investing.com -- Deutsche Bank has made several rating and target price adjustments across the European pharmaceuticals space ahead of second-quarter earnings, flagging continued weakness in the sector and potential opportunities in select names.
investing.com·4mo ago

Latest CVAC News

View

Advertisement|Remove ads.

Advertisement|Remove ads.